10 May 2012 - New Teva Representative Joins Mesoblast Board of Directors
17 April 2012 - Intervertebral Disc Repair Phase 2 Trial Update
26 March 2012 - Mesoblast Presents Program Updates At Credit Suisse 15th Asia Investment Conference
27 February 2012 – Half Year Results: Mesoblast Posts Strong Cash Balance
31 January 2012 - Mesoblast Receives FDA Clearance for Phase 2 Clinical Trial of Proprietary Stem Cell Therapy in Type 2 Diabetes
11 January 2012 – Presentation to 30th Annual JP Morgan Healthcare Conference in USA
The American Heart Association estimates 80 million American adults (approximately 1 in 3) have one or more forms of cardiovascular diseases...
Stem cell therapy is emerging as the new paradigm for treating and potentially curing human disease. It involves the use of living cells...
Mesoblast is aiming to produce therapeutics for the treatment of heart conditions, blood vessel diseases of the eyes and legs bone marrow regeneration after cancer...
10 May 2012 - New Teva Representative Joins Mesoblast Board of Directors